Drug Profile
Research programme: drug discovery - Bristol-Myers Squibb
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom (PO)
- 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
- 11 Sep 2012 Early research in Undefined indication in United Kingdom (PO)